 LAVAL, Quebec--BUSINESS WIRE--BELLUS Health Inc. Nasdaq:BLU; TSX:BLU BELLUS Health or the Company, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough RCC and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society ERS International Congress 2022, being held in Barcelona, 